NextCure
Manufacturing · Maryland, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
9000 Virginia Manor Rd Ste 200, Beltsvil...Phone Number
(240) 399-4900Website
www.nextcure.comRevenue
$27.7 MillionStock Symbol
NXTCIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
3
2
1
1
1
1
About NextCure
NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases.Explore more
NextCure Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is NextCure your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if NextCure is spiking on competitors!
Funding: Get notified immidiatlly once NextCure has new funding data
Congratulate Masked Content for being promoted to Masked Content at NextCure
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when NextCure launches new products
NextCure, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on NextCure recently announced quarterly report
Click to see if NextCure had a recent Job posting/layoffs
Check if NextCure has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined NextCure as Masked Content
Find 2 more new buyers
Compare Similar Companies to NextCure
Compare insights from companies similar to NextCure, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
NextCure is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
NextCure is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about NextCure.
NextCure financials insights
Gather financial insights about NextCure, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Series A
$67M
2019
Stock Offering
$86.3M
Stock Offering
$150M
2025
Other Financing Round
$21.5M
NextCure Tech Stack
A closer look at the technologies used by NextCure
Most Recent Scoops
Open Position
Open Position
Open Position
Earnings
NextCure has reported a net loss of $55.8 million for FY 2025, compared to $55.7 million in Q1 2025.
Earnings, Finance
Open Position
NextCure News & Media
NextCure, Inc. (NXTC) Discusses Preliminary Phase I Data for SIM0505 in Platinum-Resistant Ovarian Cancer and Uterine Serous Carcinoma Transcript
NextCure, Inc. (NXTC) Discusses Preliminary Phase I Data for SIM0505 in Platinum-Resistant Ovarian Cancer and Uterine Serous Carcinoma June 2, 2026 8:00 AM...NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026
BELTSVILLE, Md., June 01, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel therapies to treat cancer, and Simcere Zaiming Pharmaceutical Co., Ltd., (Simcere Zaiming) an oncology-focused biopharmaceutical company and a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096), today announced the presentation of positive Phase 1 dose escalation data for SIM0505 at the American Society for Clinical OnNextCure Provides Business Update and Reports First Quarter 2026 Financial Results
BELTSVILLE, Md., May 07, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel therapies to treat cancer, today provided a business update and reported first quarter 2026 financial results.NextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic Cancers
BELTSVILLE, Md., May 04, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer and Simcere Zaiming Pharmaceutical Co., Ltd., (Simcere) an oncology-focused biopharmaceutical company and a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096), today announced initiation of the dose optimization portion of the Phase 1 study of SIM0505, focusin
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding NextCure
Sign Up For FreeTo access detailed company insights
NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases.... Read More
